Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RFX3 divergent transcript (RFX3-DT)
- Target
- RFX3-DT
- Molecular classification
- Long non-coding RNA (lncRNA), Divergent transcript
01
Overview
RFX3 divergent transcript (RFX3-DT) is a long non-coding RNA transcribed near the regulatory factor X3 (RFX3) gene locus, typically within 300–500 nucleotides of the RFX3 gene. It has alternative aliases including CVAT7 and RFX3-AS1[2][6][8]. RFX3-DT is classified as a divergent transcript, which denotes its non-coding character and its position near and orientation divergent from a protein-coding gene. There are no established therapeutic, biomarker, or direct disease associations for RFX3-DT, and it is not considered a receptor, enzyme, or classical pharmacological target[2][8]. Its primary relevance arises in genomic annotation and studies of long non-coding RNAs, where such transcripts can participate in the local regulation of neighboring coding genes, though no specific role or mechanism for RFX3-DT is currently characterized in the literature[8].
- Other names
- CVAT7RFX3-AS1
02
Mechanism of action
None.
03
Biological functions
Regulation of neighboring gene expression (potential regulatory effects on RFX3 protein-coding gene, inferred from the general behavior of divergent transcripts)
04
Disease associations
Other (No direct links as a disease gene; however, the protein-coding RFX3 gene—distinct from RFX3-DT—is involved in ciliary dysfunction disorders; RFX3-DT itself does not have established disease associations)
Beyond the preview
Go deeper on RFX3 divergent transcript (RFX3-DT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RFX3 divergent transcript (RFX3-DT).